Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.43 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863053 | 0.91 | CYP4F2 (0.55) | CA2CYP4F2CYP4A11SMN1; SMN2NPC1 | |
| SCHEMBL5863152 | 0.88 | CA2 (0.54) | CA2CYP4F2CYP4A11NPC1RAB9A | |
| SCHEMBL5863054 | 0.87 | CA2 (0.49) | CA2SMN1; SMN2NPC1RAB9ARARA | |
| SCHEMBL5863106 | 0.84 | TDP1 (0.52) | BCL2CA2SMN1; SMN2RARARARB | |
| SCHEMBL4729076 | 0.83 | BCL2 (0.57) | BCL2CA2CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL5863364 | 0.81 | TSHR (0.46) | CA2CYP4F2CYP4A11SMN1; SMN2RAB9A | |
| SCHEMBL29677944 | 0.80 | CA12 (0.59) | BCL2CA2PDK2CA12CA1 | |
| SCHEMBL4726691 | 0.79 | BCL2 (0.56) | BCL2CA2CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL5556244 | 0.78 | CA12 (0.66) | CA2SMN1; SMN2NPC1RAB9ARARA | |
| SCHEMBL13232626 | 0.78 | BCL2 (0.55) | BCL2CA2CYP4F2CYP4A11SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052449-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | BCL2 4130/4885CA2 2525/4885CYP4F2 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.